TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24764124
Drug: Veliparib (ABT-888)
Normalized name: ABT-925
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (ABT-888) 40 mg twice daily on days 1-7 and temozolomide (TMZ) 150 mg/m(2)/day for cycle 1, then 200 mg/m(2)/day for cycle 2 onwards on days 1-5 q28 days.
Study: 24764124
Drug: Veliparib and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib and TMZ combination treatment.
Study: 24766766
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester (STAEST) intervention, doses varied from 0.8 to 8.8 g/d, duration from 4 to 52 weeks.
Study: 24771350
Drug: ASP9521 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP9521 (30 mg/day for 12 weeks)
Study: 24773782
Drug: Anti-HEV IgG
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HEV IgG antibodies
Study: 24777247
Drug: Repeated infusions
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated infusions of CAR-T cells
Study: 24777716
Drug: Eculizumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (600 mg weekly for 4 weeks, 900 mg in week 5, and 900 mg every 2 weeks thereafter)
Study: 24782620
Drug: Hansenula-derived PEGylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hansenula-derived PEGylated interferon alpha-2a plus ribavirin for 12 weeks (weekly subcutaneous injection of PEG-IFN-alpha-2a plus daily oral ribavirin).
Study: 24782620
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment course up to 72 weeks for patients who were PCR-negative at week 48 but had at least one PCR-positive test during therapy.
Study: 24782620
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment schedule of PEG-IFN-alpha-2a plus ribavirin.
Study: 24782620
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of liver transaminases before and after treatment.
Study: 24782684
Drug: HMBFA-HIIT (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMBFA-HIIT (3 g per day of HMBFA)
Study: 24786603
Drug: Sorafenib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (200 mg BID) combined with radiation therapy (60 Gy in 2 Gy fractions) and temozolomide (75 mg/m² daily)
Study: 24786603
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg BID) combined with radiation therapy and temozolomide
Study: 24787738
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (500 mg, once daily) for 1 or 2 days followed by oral azithromycin (250 mg once daily) to complete a total of 7 days treatment
Study: 24789707
Drug: Functional L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional L lesion
Study: 24789707
Drug: Clots categorized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clots categorized as L lesion
Study: 24794216
Drug: High on-aspirin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High on-aspirin platelet reactivity (OAR)
Study: 24794216
Drug: High vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High vs. normal on-treatment platelet reactivity
Study: 24794806
Drug: SAR103168, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR103168, a novel multi-targeted kinase inhibitor
Study: 24794816
Drug: Nicotinamide (2-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (2-8 g oral) for 5 days and 8 weeks, with doses gradually escalated during phases 1 and 2.
Study: 24794816
Drug: Nicotinamide (3.5-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (3.5-6 g daily) for 8 weeks.
Study: 24794816
Drug: Nicotinamide (high-dose)
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide (high-dose)
Study: 24797180
Drug: Reduced-toxicity conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-toxicity conditioning (RTC) regimen of BU 12.8-16 mg/kg, fludarabine 180 mg/m², alemtuzumab 54 mg/m² (BFA) before HLA-matched sibling donor transplantation
Study: 24797373
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of spiritual care providers (discussions about patient's end-of-life wishes, preparation for family conference, total number of activities performed)
Study: 24798021
Drug: Oral posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral posaconazole with intravenous micafungin bridging (POS-MIC)
Study: 24798021
Drug: Oral posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral posaconazole (POS)
Study: 24800949
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m², Pazopanib 400 mg, Lapatinib 1000 mg
Study: 24800949
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m² with Pazopanib 400 mg and Lapatinib 1000 mg
Study: 24801836
Drug: Intratumoral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral and intramuscular injections of polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose (poly-ICLC)
Study: 24802773
Drug: Eltrombopag (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (50 mg, days 5-32) + Dexamethasone (40 mg by mouth, days 1-4)
Study: 24807459
Drug: Linifanib (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib (7.5 mg and 12.5 mg) in combination with carboplatin (AUC = 6 mg/mL/min) and paclitaxel (200 mg/m²)
Study: 24807459
Drug: Linifanib (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib (12.5 mg)
Study: 24807889
Drug: VTX-2337 (0.1-3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTX-2337 (0.1-3.9 mg/m(2)) administered subcutaneously on days 1, 8, and 15 of each 28-day cycle
Study: 24808483
Drug: Antenatal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroid treatment
Study: 24811751
Drug: varenicline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: varenicline (0.25 mg BID, 0.5 mg BID, 1 mg BID)
Study: 24811754
Drug: SC serum-free
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC serum-free interferon β-1a 44 μg or 22 μg 3 times weekly for 12 months
Study: 24814620
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine (Cervarix©)
Study: 24814743
Drug: Comprehensive, validated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive, validated questionnaire on functional impairments and QoL administered at diagnosis and after one, two, and five years.
Study: 24816856
Drug: Eliglustat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliglustat (50 or 100 mg) self-administered orally twice daily
Study: 24816908
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ganitumab (18 mg/kg) and conatumumab (15 mg/kg)
Study: 24817603
Drug: Sorafenib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (200 mg BiD for 5 days every week) + Bevacizumab (5 mg/kg intravenously every 14 days)
Study: 24819685
Drug: OPB-31121 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-31121 at 300 mg BID
Study: 24819685
Drug: OPB-31121 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-31121 at 350 mg BID
Study: 24819685
Drug: Pharmacokinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics of OPB-31121
Study: 24821883
Drug: Neoadjuvant dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) with pegfilgrastim support
Study: 24823675
Drug: Anaemia (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaemia (defined as haemoglobin <12 g/dL for women and <13 g/dL for men)
Study: 24824628
Drug: Cisplatin 25
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m² on days 1-3 and gemcitabine 1,000 mg/m² on days 1 and 8 for up to 8 cycles
Study: 24824852
Drug: Weekly dose-intensified
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dose-intensified cisplatin (30 mg/m²), epirubicin (50 mg/m²), and paclitaxel (80 mg/m²) regimen for eight cycles
Study: 24824852
Drug: Weekly dose-intensified
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dose-intensified cisplatin, epirubicin, and paclitaxel regimen
Study: 24825411
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg once daily (days 1-5 and 12-16)
Study: 24825411
Drug: Darunavir 800
Normalized name: darunavir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir 800 mg/ritonavir 100 mg once daily (days 6-16)
Study: 24826798
Drug: sorafenib added
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib added to endocrine therapy
Study: 24827135
Drug: Panitumumab (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (9 mg/kg) combined with FEC100 (5-fluorouracil 500 mg/m², epidoxorubicin 100 mg/m², cyclophosphamide 500 mg/m²) followed by docetaxel (100 mg/m²), administered for eight cycles q.3 weeks and four cycles of FEC100 q.3 weeks, followed by four cycles of docetaxel q.3 weeks.
Study: 24827135
Drug: Panitumumab in
Normalized name: panitumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab in combination with FEC100 followed by docetaxel
Study: 24829202
Drug: Oral 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 6-mercaptopurine (6MP)
Study: 24829343
Drug: RV144 HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV144 HIV-1 vaccine
Study: 24829492
Drug: 5-month fish-oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-month fish-oil supplementation providing 1.4 g DHA/d plus 1.8 g EPA/d
Study: 24829746
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg CEA peptide (Arm A)
Study: 24829746
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg CEA peptide (Arm B)
Study: 24829746
Drug: 1000 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg CEA peptide (Arm C)
Study: 24829756
Drug: pINGmuTyr vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pINGmuTyr vaccine at 1.5 mg dose
Study: 24829756
Drug: pINGmuTyr vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pINGmuTyr vaccine at 0.2 mg and 0.5 mg doses
Study: 24829756
Drug: pINGmuTyr vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pINGmuTyr vaccine
Study: 24829756
Drug: pINGmuTyr vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pINGmuTyr vaccine followed by ipilimumab
Study: 24829759
Drug: Recombinant Interleukin
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Interleukin 21 (IL-21) plus sorafenib (400 mg twice daily)
Study: 24830339
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of inhaled beclometasone dipropionate and formoterol fumarate dry powder inhalers
Study: 24830339
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of inhaled beclometasone dipropionate and formoterol fumarate dry powder inhalers
Study: 24831981
Drug: Lenalidomide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (15 mg oral on days 1-14) plus R-CHOP21 (375 mg/m² rituximab, 750 mg/m² cyclophosphamide, 50 mg/m² doxorubicin, 1.4 mg/m² vincristine on day 1, and 40 mg/m² prednisone on days 1-5)
Study: 24834795
Drug: Denosumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (120 mg) subcutaneously every four weeks, with additional doses on study days 8 and 15.
Study: 24836963
Drug: Etravirine (ETV)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine (ETV) (once or twice daily)
Study: 24839031
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg subcutaneous monthly for 6 months
Study: 24843416
Drug: BIAsp70 (thrice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIAsp70 (thrice-daily injections)
Study: 24843714
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg/day
Study: 24843520
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus low-dose pravastatin (10-20 mg/day, average 8.3 mg during follow-up)
Study: 24843528
Drug: glibenclamide 1.25-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: glibenclamide 1.25-2.5 mg/day
Study: 24843582
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg ginsam
Study: 24843582
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg ginsam
Study: 24843582
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg ginsam
Study: 24843631
Drug: Exenatide twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice-daily (EBID)
Study: 24843697
Drug: Atorvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin therapy (10, 20, and 40 mg)
Study: 24843710
Drug: Insulin regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin regimen change
Study: 24843716
Drug: Empagliflozin 1
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 1 mg
Study: 24843782
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Pioglitazone (comparison)
Study: 24846037
Drug: Genotype-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-directed therapy
Study: 24846037
Drug: Any oncogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any oncogenic driver(s) without genotype-directed therapy
Study: 24846037
Drug: Matched targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched targeted therapy or trial
Study: 24846496
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 110 mg oral dose
Study: 24848086
Drug: Automated, repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated, repetitive filling of 100 mL warm saline starting with an empty bladder
Study: 24848086
Drug: Automated, repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated, repetitive filling of 100 mL warm saline starting with a low prefilled bladder volume (100 mL)
Study: 24848086
Drug: Automated, repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated, repetitive filling of 100 mL warm saline starting with a high prefilled bladder volume (persistent desire to void)
Study: 24848086
Drug: Automated, repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated, repetitive filling of 100 mL cold saline starting with an empty bladder
Study: 24849582
Drug: Amuvatinib (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amuvatinib (100-800 mg/day every 21 days)
Study: 24852920
Drug: SR Fampridine
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SR Fampridine 10 mg BID for 4 weeks
Study: 24853169
Drug: Benznidazole 5-8
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 5-8 mg/kg/day BID for 60 days
Study: 24853169
Drug: Benznidazole treatment
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole treatment in children under 7 years
Study: 24855165
Drug: Optimized insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimized insulin injection technique
Study: 24855165
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin injection technique
Study: 24857248
Drug: Antiplatelet/anticoagulation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet/anticoagulation therapy
Study: 24857280
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline nasal irrigation (twice daily for 8 weeks)
Study: 24857280
Drug: Intranasal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroid alone
Study: 24857345
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day, escalated by 50 mg every 2 weeks to a maximum of 300 mg/day)
Study: 24859366
Drug: SL-401 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SL-401 at 12.5 μg/kg intravenously over 15 minutes daily for up to 5 doses
Study: 24859907
Drug: Panobacumab (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobacumab (three doses of 1.2 mg/kg)
Study: 24862830
Drug: Metformin; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin; specific dosage and duration not mentioned
Study: 24867540
Drug: Neoadjuvant short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant short-course proton-based radiation with capecitabine (5 daily doses of 5 GyE)
Study: 24867717
Drug: Natrelle round
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natrelle round silicone implants (augmentation)
Study: 24867717
Drug: Natrelle round
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natrelle round silicone implants (revision-augmentation)
Study: 24867717
Drug: Natrelle round
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natrelle round silicone implants (reconstruction)
Study: 24867717
Drug: Submuscular placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submuscular placement of implants (augmentation)
Study: 24867717
Drug: Overall implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall implants (magnetic resonance imaging cohort)
Study: 24867717
Drug: Augmentation subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation subjects
Study: 24867717
Drug: Revision-augmentation subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revision-augmentation subjects
Study: 24868099
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg per day until disease progression or intolerable adverse events
Study: 24872229
Drug: Subcutaneous interleukin
Normalized name: interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interleukin 2 (1.5 million IU/d for 5 days, followed by three 5-day courses of 3 million IU/d at weeks 3, 6, and 9)
Study: 24872229
Drug: Subcutaneous interleukin
Normalized name: interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interleukin 2
Study: 24872402
Drug: Tirasemtiv 375
Normalized name: Tirasemtiv
DrugBank: Tirasemtiv (DB12209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirasemtiv 375 mg
Study: 24872402
Drug: Tirasemtiv 750
Normalized name: Tirasemtiv
DrugBank: Tirasemtiv (DB12209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirasemtiv 750 mg
Study: 24872402
Drug: Tirasemtiv 500
Normalized name: Tirasemtiv
DrugBank: Tirasemtiv (DB12209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirasemtiv 500 mg (after dose adjustment)
Study: 24872728
Drug: Early follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early follow-up by telephone consultations (4 and 14 days post-discharge) in addition to conventional treatment
Study: 24872728
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment following discharge from hospital
Study: 24875132
Drug: AZD8931 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 monotherapy (40/60/80 mg bid for 21 days)
Study: 24875132
Drug: AZD8931 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 40 mg bid plus paclitaxel 90 mg/m² (days 1, 8, 15 of 28-day cycle)
Study: 24875132
Drug: AZD8931 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 monotherapy and combination therapy
Study: 24876243
Drug: Community interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community interventions (e.g., preparedness bracelets and stroke warning magnets)
Study: 24878054
Drug: Congenital adrenal
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congenital adrenal hyperplasia (CAH) treatment
Study: 24878054
Drug: Glucocorticoid only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid only treatment in women
Study: 24879333
Drug: Alisertib ECT
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib ECT (50 mg BID for 7 days)
Study: 24879333
Drug: Alisertib ECT
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib ECT (doses ≥ 40 mg BID)
Study: 24879786
Drug: Previous 23-valent
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous 23-valent polysaccharide vaccine (PPSV23)
Study: 24879844
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hsTnT and NT-proBNP